Autobahn Therapeutics
Manufacturing · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
9880 Campus Point Dr, San Diego, Califor...Phone Number
(858) 257-3418Website
www.autobahntx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Autobahn Therapeutics
Autobahn Therapeutics is dedicated to enhancing the health of individuals affected by central nervous system (CNS) disorders through innovative regenerative medicines. The company focuses on developing next-generation therapies that restore brain health, addressing both rare and common diseases. Their approach includes a brain-targeting chemistry platform and biomarker-driven development strategies to ensure effective treatment outcomes. Autobahn Therapeutics aims to provide hope and improved futures for patients suffering from progressive and debilitating CNS conditions.Explore more
Autobahn Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Autobahn Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Autobahn Therapeutics had a recent Job posting/layoffs
Check if Autobahn Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Autobahn Therapeutics recently announced quarterly report
Product Launch: Get notified when Autobahn Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Autobahn Therapeutics
Check out if Autobahn Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Autobahn Therapeutics has new funding data
Autobahn Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Autobahn Therapeutics
Find 3 more new buyers
Compare Similar Companies to Autobahn Therapeutics
Compare insights from companies similar to Autobahn Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Autobahn Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Autobahn Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Autobahn Therapeutics.
Autobahn Therapeutics financials insights
Gather financial insights about Autobahn Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Other Financing Round
$32.7M
2024
Series C
$100M
Autobahn Therapeutics Tech Stack
A closer look at the technologies used by Autobahn Therapeutics
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Product Development, Product Management, Legal Affairs, Governmental Affairs & Regulation, Medical Research, Pharmaceuticals, Clinical Operations, Regulations
Funding
Event
Events
Event
Events
Autobahn Therapeutics News & Media
Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the company will present the clinical results from its completed Phase 1 trial of ABX-002 at the 2025 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, taking place May 27-30, 2025, in Scottsdale, AZ. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selectiveAutobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression
SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the initiation of a Phase 2 clinical trial evaluating ABX-002, its highly potent, oral, thyroid hormone beta receptor (TRβ) selective agonist, as an adjunctive treatment in adults with bipolar depression. The Phase 2 trial aims to establish biological and clinical proof-of-concept for ABX-002 in bipolAutobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced that Kevin Finney, President and Chief Executive Officer, will participate in the following upcoming investor conferences: 2024 Stifel Healthcare Conference Presentation: Monday, November 18, 2024 at 9:10 a.m. ET Location: New York, NY 2024 Jefferies London Healthcare Conference Investor Meetings: WedAutobahn Therapeutics Announces FDA Clearance of IND Application for ABX-002 as an Adjunctive Treatment for Bipolar Depression
SAN DIEGO--(BUSINESS WIRE)--Autobahn Therapeutics, a biotechnology company developing restorative treatments for people affected by neuropsychiatric and neuroimmunologic disorders, today announced the clearance of an investigational new drug (IND) application by the U.S. Food and Drug Administration (FDA) to support initiation of a Phase 2 trial of ABX-002 as an adjunctive treatment for patients with bipolar depression. ABX-002 is a highly potent, oral, thyroid hormone beta receptor (TRβ) selec
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Autobahn Therapeutics
Sign Up For FreeTo access detailed company insights
Autobahn Therapeutics is dedicated to enhancing the health of individuals affected by central nervous system (CNS) disorders through innovative regenerative medicines. The company focuses on developing next-generation therapies that restore brain health, addressing both rare and common diseases. Their approach includes a brain-targeting chemistry p... Read More
